TBG-siCDK11-treated or TBG-siCK2-treated MDA-MB-231 tumors showed reduced target protein expression and response parameters that included decreased proliferation, tumor mass, and tumor volume relative to controls. Here, SERPINA7 is linked to neoplasm.